Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Inclusion Criteria:

1. Female aged between 18 and 70;
2. Recurrence or metastasis OF TNBC confirmed by histological or cytological methods,TNBC definitions of ER, PR and HER-2 are negative, if there is metastasis pathology,the histological pathology of metastasis shall prevail.ER and PR negative were definedas ER < 10% positive and PR < 10% positive.
3. Disease progression after at least one prior systemic treatment and anthracyclineand/or taxane use;Note: For neoadjuvant/adjuvant therapy, recurrence or diseaseprogression during treatment or within 6 months of discontinuation of treatment shouldbe counted as first-line systemic treatment failure;
4. There should be at least one measurable lesion according to the efficacy evaluationcriteria for solid tumors (RECIST version 1.1)

Exclusion Criteria:

1. The number of previous treatment lines (including postoperative adjuvant therapy) >4lines
2. symptomatic central system metastases.Patients with stable asymptomatic BMS who havereceived brain radiation and who have at least one other evaluable target in additionto the BMS can be enrolled (evaluable target should be at least 4 weeks away from thelast radiotherapy).
3. New bisphosphonate or dinoselmer treatment for bone metastases was initiated within 28days prior to study initiation.(Subjects are permitted if they have already beentreated with bisphosphonate or dinoselmer for at least 4 weeks of optimal stableadministration prior to study initiation.)Subjects already enrolled in this study maybegin treatment with bisphosphonate or dinoselmer for bone metastases after the firstpost-treatment evaluation